CMV-TCR-T Cells for CMV Infection After Allogenic HSCT

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Chinese PLA General Hospital
Updated on 26 December 2021


This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after allogenic HSCT.


Cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (HSCT) is common and can be lethal without prompt treatment. In this prospective study, HLA-A*02:01/11:01/24:02-restricted CMV-specific T cell receptor (TCR) will be introduced into donor T cells by ex vivo lentiviral transduction to generate CMV-TCR-T cells. An escalated dose ranging from 1×10^4 to 1×10^7 of CMV-TCR-T cells will be infused into patients with CMV infection. The safety, efficacy, pharmacokinetics and cytokine levels of allogenic CMV-TCR-T cell therapy will be evaluated.

Condition CMV Infection After Allogenic HSCT
Treatment CMV-TCR-T cells
Clinical Study IdentifierNCT05140187
SponsorChinese PLA General Hospital
Last Modified on26 December 2021


Yes No Not Sure

Inclusion Criteria

Age 1-60 years, gender unlimited. 2. Diagnosed with hematologic malignancies and have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), with CMV infection after allo-HSCT
Karnofsky Score ≥ 70 or Lansky Score ≥ 50. 4. TCR-T cell donor inclusion criteria
Age ≥ 8 years
Understand and voluntarily sign informed consent and are willing to comply with laboratory tests and other research procedures
≥ 3/6 HLA match with TCR-T cell recipients enrolled
Lymphocyte count = (0.8~4) × 10^9/L
Have sufficient venous circulation, without any symptoms that do not allow blood cell isolation

Exclusion Criteria

Patients with active aGVHD one day before TCR-T cell infusion
Patients with severe kidney disease (Cr > 3×normal value), liver damage (TBIL >2.5×upper limit of normal value, ALT and AST > 3×upper limit of normal value) or heart failure (NYHA heart function grade IV) one week before TCR-T cell infusion
Anticipated to take immunosuppressive hormones on the day of TCR-T cell infusion
Have other malignancies
Have relapsed and uncontrolled hematologic malignancies
Serologically positive for HIV-Ab or TAP-ab
Positive for EBV DNA
Anticipated to have other cell therapies in 4 week post TCR-T cell infusion
Pregnant or lactating women。
Participated in any other clinical study of drugs and medical devices before 30 days of enrollment
Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data
TCR-T cell donor exclusion criteria
Positive for any of the following: HbsAg, HBeAg, HBV-DNA, HCV-Ab, HCV-RNA, HIV-Ab, TP-Ab, EBV-DNA or CMV-DNA
Other uncontrolled infection. 3) Have taken immunosuppressive drugs 1 week before PBMC collection. 4) Any condition that would, in the investigator's judgment, make it unsuitable for the donors to be enrolled
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note